logo
Plus   Neg
Share
Email

Highlight, Merck Partner To To Evaluate Combination Of BO-112 And KEYTRUDA

Highlight Therapeutics has entered into a collaboration with a subsidiary of Merck & Co., under which the companies will focus on the phase II evaluation of the combination of BO-112, Highlight's lead program, and KEYTRUDA (pembrolizumab) anti-PD-1 therapy, in patients that have progressed on anti-PD-1-based therapy in refractory advanced malignant melanoma.

Highlight Therapeutics, formerly known as Bioncotech Therapeutics, is a private, clinical-stage company focused on immuno-oncology. Its lead drug candidate BO-112, a RNA-based therapy, is currently being investigated in a range of clinical trials as a monotherapy and in combination with checkpoint inhibitors.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration (FDA) has gone ahead with the approval of antiviral drug remdesivir as first treatment for COVID-19, notwithstanding last week's findings by the World Health Organization (WHO) that the drug is not effective for COVID-19 treatment. Thursday, Gilead Sciences announced that the FDA approved remdesivir, sold under the brand name Veklury. Integrated payments firm American Express Co. (AXP) reported Friday that net income for the third quarter declined to $1.1 billion or $1.30 per share from $1.8 billion or $2.08 per share in the prior-year quarter. Consolidated total revenues, net of interest expense, also decreased 20 percent to $8.8... The Federal Trade Commission or FTC has launched a new fraud reporting platform, using which, consumers can easily report fraud and all other consumer issues directly to the regulator. In a statement, the FTC said its new website, ReportFraud.ftc.gov, will provide a streamlined and user-friendly way to submit reports about scams, frauds, and bad business practices.
Follow RTT